MREO (Mereo BioPharma Group) Net Margin %: 0.00% (As of Mar. 2026)

What is Mereo BioPharma Group Net Margin %?

Mereo BioPharma Group MREO +3.62% 19 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates MREO with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 941 Biotechnology companies, Mereo BioPharma Group ranks worse than 91.6% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Mereo BioPharma Group's Net Income for the three months ended in Mar. 2026 was $-6.72 Mil. Mereo BioPharma Group's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Mereo BioPharma Group's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Mereo BioPharma Group's Net Margin % or its related term are showing as below:

MREO' s Net Margin % Range Over the Past 10 Years
Min: -8375.6 Med: -294.66 Max: 34.9
Current: -7142

MREO's Net Margin % is ranked worse than
91.6% of 941 companies
in the Biotechnology industry
Industry Median: -88.3 vs MREO: -7142.00

Mereo BioPharma Group (NAS:MREO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Mereo BioPharma Group Net Margin % Related Terms

Mereo BioPharma Group Net Margin % Historical Data

* Premium members only.

The historical data trend for Mereo BioPharma Group's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mereo BioPharma Group Net Margin % Chart

Mereo BioPharma Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Net Margin %

Get a 7-Day Free Trial

34.90

0.00

-294.66

0.00

-8,375.60

Mereo BioPharma Group Quarterly Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Net Margin %	Get a 7-Day Free Trial															0.00	-2,923.20	0.00	0.00	0.00

MREO vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Mereo BioPharma Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mereo BioPharma Group Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's Net Margin % distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's Net Margin % falls into.

Save Embed

19GF Score

Mereo BioPharma Group PLC MREO

Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Mereo BioPharma Group Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Mereo BioPharma Group's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin	=	Net Income (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-41.878	/	0.5
	=	-8,375.60 %

Mereo BioPharma Group's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-6.719	/	0
	=	%

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of 0.00% mean?

Mereo BioPharma Group (MREO) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Mereo BioPharma Group and its competitors. According to the industry distribution chart, Mereo BioPharma Group ranks #862 out of 941 companies in the Biotechnology industry, placing it in the top 91.6%.

Is Mereo BioPharma Group's Net Margin % too high?

Mereo BioPharma Group's current Net Margin % is 0.00%. Based on the distribution chart, Mereo BioPharma Group ranks #862 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mereo BioPharma Group has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.

How does Mereo BioPharma Group's Net Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Mereo BioPharma Group ranks #862 out of 941 companies for Net Margin %. This places Mereo BioPharma Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Mereo BioPharma Group and its competitors. Mereo BioPharma Group's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Mereo BioPharma Group stock overvalued right now?

Mereo BioPharma Group (MREO) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Mereo BioPharma Group's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For Mereo BioPharma Group (MREO), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mereo BioPharma Group Business Description

Industry Healthcare Biotechnology

Comparable Companies LSE:SBTX LSE:SAR LSE:COIL LSE:AREC LSE:IMM LSE:POLB LSE:APTA LSE:IXI LSE:HEMO LSE:FAB VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 0A9G:UK MAH0:Germany

Address One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

19GF Score

Get the complete analysis for MREO

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33

Price

View MREO Analysis

See Net Margin % data for all stocks →